Newcomer JW, et al. - Researchers examined how adjunctive brexpiprazole affects metabolic parameters and body weight in adults with major depressive disorder (MDD). This work was based on pooled data from 4 short-term studies (June 2011 to November 2016), randomized, double-blind, placebo-controlled studies in outpatients with MDD (DSM-IV-TR criteria) and inadequate response to 1–3 prior antidepressant treatments (ADTs) plus 1 prospective ADT, and one long-term extension study (October 2011 to May 2017), a 52-week (amended to 26 weeks), open-label, uncontrolled study of adjunctive brexpiprazole 0.5–3 mg/d (flexible dose; n = 2,938). As per outcomes, adjunctive brexpiprazole led to the occurrence of small changes in metabolic parameters during short-(all < 2 mg/dL) and long-term (all < 4 mg/dL, except triglycerides, 15.83 mg/dL) treatment as well as led to moderate weight gain.